We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

127 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

56% more call options, than puts

Call options by funds: $1.95M | Put options by funds: $1.25M

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

12% more funds holding

Funds holding: 113 → 127 (+14)

1.29% more ownership

Funds ownership: 29.8% → 31.09% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less capital invested

Capital invested by funds: $119M → $88.4M (-$30.7M)

Holders
127
Holders Change
+14
Holders Change %
+12.39%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
45
Reduced
33
Closed
5
Calls
$1.95M
Puts
$1.25M
Net Calls
+$696K
Net Calls Change
-$1.48M

Top Buyers

1
TSC
Two Seas Capital
New York
+$5.07M
2
OMC
Oasis Management Company
Cayman Islands
+$2.42M
3
Marshall Wace
Marshall Wace
United Kingdom
+$925K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$691K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$529K

Top Sellers

1
BC
Brookfield Corp
Ontario, Canada
-$5.19M
2
Millennium Management
Millennium Management
New York
-$1.53M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$533K
4
Simplex Trading
Simplex Trading
Illinois
-$209K
5
Goldman Sachs
Goldman Sachs
New York
-$189K
Name Holding Trade Value Shares
Change 		Change in
Stake
OQS
51
Occudo Quantitative Strategies
Florida
$81K +$100K +42,548 New
VOYA Investment Management
52
VOYA Investment Management
Georgia
$80.6K – – –
Manulife (Manufacturers Life Insurance)
53
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$80.2K -$4.05K -1,720 -4%
WMA
54
Wealth Management Associates
New Jersey
$78.1K +$26.4K +11,200 +38%
Simplex Trading
55
Simplex Trading
Illinois
$77K -$209K -88,835 -69%
XT
56
XTX Topco
Cayman Islands
$76K -$150K -63,527 -62%
Ohio Public Employees Retirement System (OPERS)
57
Ohio Public Employees Retirement System (OPERS)
Ohio
$74K +$91.8K +39,000 New
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$73.9K +$34.9K +14,832 +62%
Invesco
59
Invesco
Georgia
$72K +$6.89K +2,925 +8%
Prudential Financial
60
Prudential Financial
New Jersey
$65K +$294 +125 +0.4%
CM
61
Caption Management
Oklahoma
$64K -$40.1K -17,016 -33%
SOW
62
State of Wyoming
Wyoming
$63K +$77.3K +32,832 New
AllianceBernstein
63
AllianceBernstein
Tennessee
$61K +$17.9K +7,600 +31%
SSA
64
Schonfeld Strategic Advisors
New York
$61K +$75.1K +31,900 New
Franklin Resources
65
Franklin Resources
California
$60K +$198 +84 +0.3%
SG Americas Securities
66
SG Americas Securities
New York
$56K +$18.7K +7,957 +37%
VCP
67
Verus Capital Partners
Arizona
$53K +$65.2K +27,700 New
ProShare Advisors
68
ProShare Advisors
Maryland
$47K +$1.89K +802 +3%
Two Sigma Investments
69
Two Sigma Investments
New York
$47K +$57.5K +24,442 New
Lazard Asset Management
70
Lazard Asset Management
New York
$44K – – –
AQR Capital Management
71
AQR Capital Management
Connecticut
$44K +$7.99K +3,392 +17%
LSA
72
Leonteq Securities AG
Switzerland
$43.9K +$11.8K +5,000 +28%
ACM
73
Aquatic Capital Management
Illinois
$41K +$45.9K +19,500 +929%
PFO
74
Pathstone Family Office
New Jersey
$38.1K +$23.5K +10,000 +100%
Jane Street
75
Jane Street
New York
$36K -$55.9K -23,732 -56%
1 2
3
4 5

ABUS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2022, worth a combined $88.4M — down 26% from $119M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ABUS positions and 5 closed out — a net gain of 15 holders — while 45 added to existing stakes and 33 trimmed.

The largest buyer was Two Seas Capital, adding an estimated $5.07M. The largest seller was Brookfield Corp, exiting entirely with an estimated $5.19M sold.

  • 127 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $88.4M of Arbutus Biopharma stock for Q3 2022, down 26% quarter-over-quarter.
  • 20 funds opened new Arbutus Biopharma positions in Q3 2022 and 5 closed out, a net change of +15 holders.
  • The largest Arbutus Biopharma buyer in Q3 2022 was Two Seas Capital, an estimated $5.07M added.
  • The largest Arbutus Biopharma seller in Q3 2022 was Brookfield Corp, an estimated $5.19M sold.

Based on aggregated 13F filings for Q3 2022.